{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:59:37Z","timestamp":1792004377534,"version":"4.4.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We describe the first case of cefepime-zidebactam treatment-emergent resistance associated with clinical failure in a patient with Pseudomonas aeruginosa pneumonia. During treatment, cefepime-zidebactam minimum inhibitory concentrations increased from 8\/8 to 32\/32\u2005mg\/L. Whole-genome sequence analysis showed new mutations in the MexAB-OprM efflux operon that were associated with cross-resistance to ceftazidime-avibactam and imipenem-relebactam.<\/jats:p>","DOI":"10.1093\/cid\/ciaf638","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T12:51:52Z","timestamp":1763211112000},"page":"44-48","source":"Crossref","is-referenced-by-count":11,"title":["First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in\n                    <i>Pseudomonas aeruginosa<\/i>"],"prefix":"10.1093","volume":"82","author":[{"given":"Ava J","family":"Dorazio","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8659-4238","authenticated-orcid":false,"given":"Samuel L","family":"Aitken","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Michigan College of Pharmacy , Ann Arbor, Michigan ,","place":["USA"]},{"name":"Department of Pharmacy, Michigan Medicine , Ann Arbor, Michigan ,","place":["USA"]},{"name":"Division of Infectious Diseases, University of Michigan Medical School , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3723-1326","authenticated-orcid":false,"given":"Virginia M","family":"Pierce","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan Medical School , Ann Arbor, Michigan ,","place":["USA"]},{"name":"Department of Pediatrics, University of Michigan Medical School , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7167-6368","authenticated-orcid":false,"given":"Ellen G","family":"Kline","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7818-905X","authenticated-orcid":false,"given":"Kevin M","family":"Squires","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M","family":"Pogue","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Michigan College of Pharmacy , Ann Arbor, Michigan ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9794-5665","authenticated-orcid":false,"given":"Ryan K","family":"Shields","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]},{"name":"Center for Innovative Antimicrobial Therapy, University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]},{"name":"Antibiotic Management Program, University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"2026020904072249800_ciaf638-B1","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1093\/jac\/dkac233","article-title":"Antimicrobial activity of cefepime\/zidebactam (WCK 5222), a \u03b2-lactam\/\u03b2-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018\u201319)","volume":"77","author":"Sader","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026020904072249800_ciaf638-B2","doi-asserted-by":"crossref","first-page":"e02529-16","DOI":"10.1128\/AAC.02529-16","article-title":"WCK 5107 (zidebactam) and WCK 5153 are novel inhibitors of PBP2 showing potent \u201c\u03b2-lactam enhancer\u201d activity against Pseudomonas aeruginosa, including multidrug-resistant metallo-\u03b2-lactamase-producing high-risk clones","volume":"61","author":"Moya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026020904072249800_ciaf638-B3","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/jac\/dkaa036","article-title":"Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa","volume":"75","author":"Moya","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026020904072249800_ciaf638-B4","doi-asserted-by":"crossref","first-page":"e0111823","DOI":"10.1128\/mbio.01118-23","article-title":"Transcending the challenge of evolving resistance mechanisms in Pseudomonas aeruginosa through \u03b2-lactam-enhancer-mechanism-based cefepime\/zidebactam","volume":"14","author":"Hujer","year":"2023","journal-title":"mBio"},{"key":"2026020904072249800_ciaf638-B5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jgar.2025.07.009","article-title":"Successful use of cefepime\/zidebactam in deep-seated infections due to extensively drug-resistant Pseudomonas aeruginosa\u2014a case series","volume":"44","author":"Shah","year":"2025","journal-title":"J Glob Antimicrob Resist"},{"key":"2026020904072249800_ciaf638-B6","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/trstmh\/trae049","article-title":"Difficult to treat Pseudomonas: successful salvage therapy with cefepime-zidebactam","volume":"118","author":"Sebastian","year":"2024","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2026020904072249800_ciaf638-B7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12941-023-00606-x","article-title":"Compassionate use of a novel \u03b2-lactam enhancer-based investigational antibiotic cefepime\/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report","volume":"22","author":"Dubey","year":"2023","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2026020904072249800_ciaf638-B8","doi-asserted-by":"crossref","first-page":"e0050023","DOI":"10.1128\/aac.00500-23","article-title":"Successful use of cefepime-zidebactam (WCK 5222) as a salvage therapy for the treatment of disseminated extensively drug-resistant New Delhi metallo-\u03b2-lactamase-producing Pseudomonas aeruginosa infection in an adult patient with acute T-cell leukemia","volume":"67","author":"Tirlangi","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026020904072249800_ciaf638-B9","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2024","edition":"34th ed"},{"key":"2026020904072249800_ciaf638-B10","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"CLSI","year":"2024","edition":"12th ed"},{"key":"2026020904072249800_ciaf638-B11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/cid\/ciae332","article-title":"Rates of resistance to ceftazidime-avibactam and ceftolozane-tazobactam among patients treated for multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia","volume":"80","author":"Shah","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026020904072249800_ciaf638-B12","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/cid\/ciac097","article-title":"Evolution of imipenem-relebactam resistance following treatment of multidrug-resistant Pseudomonas aeruginosa pneumonia","volume":"75","author":"Shields","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026020904072249800_ciaf638-B13","doi-asserted-by":"crossref","first-page":"e00084-21","DOI":"10.1128\/AAC.00084-21","article-title":"In vitro susceptibility of multidrug-resistant Pseudomonas aeruginosa following treatment-emergent resistance to ceftolozane-tazobactam","volume":"65","author":"Rubio","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026020904072249800_ciaf638-B14","doi-asserted-by":"crossref","first-page":"e1005595","DOI":"10.1371\/journal.pcbi.1005595","article-title":"Unicycler: resolving bacterial genome assemblies from short and long sequencing reads","volume":"13","author":"Wick","year":"2017","journal-title":"PLoS Comput Biol"},{"key":"2026020904072249800_ciaf638-B15","doi-asserted-by":"crossref","first-page":"e0154324","DOI":"10.1128\/aac.01543-24","article-title":"Restoring ceftolozane susceptibility: a role for diazabicyclooctane \u03b2-lactamase inhibitors?","volume":"69","author":"Dorazio","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"2026020904072249800_ciaf638-B16","doi-asserted-by":"crossref","first-page":"e0160022","DOI":"10.1128\/jcm.01600-22","article-title":"Potential of inaccurate cefiderocol susceptibility results: a CLSI AST subcommittee advisory","volume":"61","author":"Simner","year":"2023","journal-title":"J Clin Microbiol"},{"key":"2026020904072249800_ciaf638-B17","volume-title":"Class 2 device recall ETEST IMIPENEM RELEBACTAM","author":"U.S. Food and Drug Administration","year":"2021"},{"key":"2026020904072249800_ciaf638-B18","doi-asserted-by":"crossref","first-page":"dlad107","DOI":"10.1093\/jacamr\/dlad107","article-title":"In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel \u03b2-lactam\/\u03b2-lactamase inhibitors","volume":"5","author":"Shields","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"2026020904072249800_ciaf638-B19","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/jac\/dkab213","article-title":"In vitro evolution of cefepime\/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy","volume":"76","author":"Barcel\u00f3","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026020904072249800_ciaf638-B20","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1093\/jac\/dkac241","article-title":"Activity of cefiderocol, imipenem\/relebactam, cefepime\/taniborbactam and cefepime\/zidebactam against ceftolozane\/tazobactam- and ceftazidime\/avibactam-resistant Pseudomonas aeruginosa","volume":"77","author":"Lasarte-Monterrubio","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026020904072249800_ciaf638-B21","first-page":"149","article-title":"Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model","volume":"75","author":"Kidd","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026020904072249800_ciaf638-B22","volume-title":"Investigational breakpoints for cefepime\/zidebactam (FEP\/ZID)","author":"Wockhardt Breakpoint Working Group","year":"2024"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf638\/65370195\/ciaf638.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/1\/44\/65370195\/ciaf638.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/1\/44\/65370195\/ciaf638.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T09:07:33Z","timestamp":1770628053000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/1\/44\/8326496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,11,18]]},"published-print":{"date-parts":[[2026,2,9]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf638","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,15]]},"published":{"date-parts":[[2025,11,18]]}}}